
Femoston1 mg+5 mg
Unimed Unihealth MFG. Ltd.
Estradiol + Dydrogesterone is a combined hormone replacement therapy (HRT) product used in postmenopausal women who have an intact uterus.
Estradiol + Dydrogesterone is a combined hormone replacement therapy (HRT) product used in postmenopausal women who have an intact uterus. Its indications are classified below by strength of evidence.
The dydrogesterone component is added specifically to oppose the endometrial-stimulating effect of estradiol in women who still have a uterus, reducing the risk of endometrial hyperplasia and cancer that can occur with unopposed estrogen therapy. Estradiol + Dydrogesterone is not intended for women who have had a hysterectomy, unless there is a specific reason (such as endometriosis) to add a progestogen.
Note: Experience treating women older than 65 years is limited, and Estradiol + Dydrogesterone is not indicated for prevention of cardiovascular disease or dementia.
Estradiol + Dydrogesterone should be started at the lowest effective dose for the shortest duration consistent with treatment goals, and the need for continued treatment should be reassessed periodically (e.g., at least annually) by the prescribing physician.
| Regimen | Typical Dose | Schedule |
|---|---|---|
| Sequential combined (e.g., 1 mg/10 mg or 2 mg/10 mg) | Estradiol alone for the first 14 days, then estradiol + dydrogesterone for the next 14 days | One tablet daily, continuously, following the calendar pack sequence |
| Continuous combined (e.g., 1 mg/5 mg) | Estradiol + dydrogesterone taken together every day | One tablet daily, without interruption, usually for women at least 1 year postmenopausal |
Tablets should be taken orally at approximately the same time each day, with or without food, following the direction of the arrows printed on the calendar blister pack. If a dose is missed, it should be taken as soon as remembered within 12–24 hours; if more time has passed, the missed dose should be skipped (do not double up) and the physician or pharmacist consulted if breakthrough bleeding occurs.
Not applicable — Estradiol + Dydrogesterone is not indicated for use in children.
Estradiol + Dydrogesterone has not been specifically studied in renal impairment. It is contraindicated in active liver disease or a history of liver disease where liver function has not returned to normal (see Contraindications); caution and closer monitoring are advised in women with pre-existing hepatic conditions.
Side effects with Estradiol + Dydrogesterone are generally dose-related and tend to diminish with continued use. Common (may affect more than 1 in 10 people) and other reported effects include:
Less common but serious risks associated with combined HRT (including Estradiol + Dydrogesterone) include an increased risk of venous thromboembolism, stroke, and, with long-term use, breast cancer and gallbladder disease (see Precautions and Warnings and Contraindications). Patients should seek prompt medical attention for symptoms such as leg swelling/pain, sudden chest pain or breathlessness, sudden severe headache, or visual disturbance.
Estradiol + Dydrogesterone is contraindicated in the presence of any of the following:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.